Mutant receptors and their use in a nuclear receptor-based inducible gene expression system

Details for Australian Patent Application No. 2005241051 (hide)

Owner Intrexon Corporation

Inventors Kumar, Mohan Basavaraju; Palli, Subba Reddy

Agent Davies Collison Cave

Pub. Number AU-B-2005241051

PCT Pub. Number WO2005/108617

Priority 11/118,855 29.04.05 US; 60/609,424 13.09.04 US; 60/567,294 30.04.04 US

Filing date 2 May 2005

Wipo publication date 17 November 2005

Acceptance publication date 22 July 2010

International Classifications

A01K 67/00 (2006.01) Rearing or breeding animals, not otherwise provided for

A61K 31/16 (2006.01) - Amides, e.g. hydroxamic acids

A61K 31/47 (2006.01) - Quinolines

C07D 215/16 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C07K 14/435 (2006.01) Peptides having more than 20 amino acids - from animals

C07K 14/705 (2006.01) Peptides having more than 20 amino acids

C12N 15/62 (2006.01) Mutation or genetic engineering - DNA sequences coding for fusion proteins

C12P 21/06 (2006.01) Preparation of peptides or proteins - produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

21 December 2006 PCT application entered the National Phase

  PCT publication WO2005/108617 Priority application(s): WO2005/108617

14 June 2007 Assignment before Grant

  RheoGene, Inc. The application has been assigned to Intrexon Corporation

22 July 2010 Application Accepted

  Published as AU-B-2005241051

18 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005241056-1,2,4-oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

2005241046-Compositions comprising tetrafluoropropene and carbon dioxide